

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 January 2025 (30.01.2025)



(10) International Publication Number
WO 2025/019952 A1

(51) International Patent Classification:

A61K 51/08 (2006.01) A61K 47/22 (2006.01)
A61K 47/12 (2006.01) A61P 35/00 (2006.01)
A61K 47/18 (2017.01) C07K 5/037 (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(21) International Application Number:

PCT/CA2024/050996

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:

26 July 2024 (26.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/515,943 27 July 2023 (27.07.2023) US

(71) Applicant: **FUSION PHARMACEUTICALS INC.**
[CA/CA]; 270 Longwood Road South, Hamilton, Ontario
L8P 0A6 (CA).

(72) Inventors: **ROLAND, Kevin**; 3061 Preserve Drive,
Oakville, Ontario L6M 0W6 (CA). **DUFFY, Ian Ruixi-**
ang; 268 Ellen Davidson Drive, Oakville, Ontario L6M 0V2
(CA). **BHALLA, Rajiv**; 229 Grosvenor Avenue North,
Hamilton, Ontario L8L 7T1 (CA).

(74) Agent: **SMART & BIGGAR LP**; P.O. Box 2999, Sta-
tion D., 1000-55 Metcalfe Street, Ottawa, Ontario K1P 5Y6
(CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: PSMA-TARGETED RADIOPHARMACEUTICALS FOR TREATMENT OF CANCER

(57) Abstract: Pharmaceutical compositions comprising ²²⁵Ac-radioconjugate of Formula I and methods of using the same for treating PSMA-expressing cancer. Also disclosed herein are methods for preparing said pharmaceutical compositions.

WO 2025/019952 A1